• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
BB1
Click for more information
0.00% 32.0¢

BLINKLAB LIMITED - News & Media

Market Cap $18.26M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Medical Devices

BlinkLab Limited (ASX: BB1) is a trailblazer in digital healthcare, leveraging AI and... BlinkLab Limited (ASX: BB1) is a trailblazer in digital healthcare, leveraging AI and machine learning in mobile applications to revolutionise neurodevelopmental condition diagnosis like ASD and ADHD. Born from extensive research at Princeton University, BlinkLab offers early detection and effective intervention solutions through its smartphone-based diagnostic platform. The company is committed to improving mental health care globally, starting with the youngest patients.More

Recently Updated

Corporate Spotlight

BlinkLab Limited (ASX: BB1) is a trailblazer in digital healthcare, leveraging AI and machine learning in mobile applications to revolutionise neurodevelopmental condition diagnosis like ASD and ADHD.
View the full Corporate Spotlight arrow Created with Sketch.

WEBINAR REPLAY: BLINKLAB

Articles & Videos

BlinkLab partnership with US smart-tech Turning Pointe raises hopes for autism kids

BlinkLab partners with US-based Turning Pointe Autism Foundation for clinical study ahead of its FDA registration study later in the year

02 May 2024 11:19 (AEST)

Why Princeton Professor rates BlinkLab's autism & ADHD screening app

In this interview with Sonia Madigan, Professor Sam Wang of Princeton University discusses the development and potential of BlinkLab's (ASX:BB1) AI-driven smartphone app, designed to screen for autism and ADHD.

30 Apr 2024 15:11 (AEST)

BlinkLab up as much as 50% on debut

BlinkLab (ASX:BB1) has traded up as much as 50 per cent on listing on the ASX this morning, breaking the ASX IPO drought.

04 Apr 2024 14:09 (AEDT)

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to detect autism and ADHD. It’s listing on the ASX next Thursday (April 4) under the code BB1. BlinkLab’s development is being led by chair Brian Leedman - a founder of ResApp Health - the cough analysis app sold to Pfizer two years ago in a $179 million deal.

28 Mar 2024 08:54 (AEDT)



(20min delay)
Last
32.0¢ 		Change
0.000(0.00%) 		Mkt cap ! $18.26M
Open High Low Value Volume
32.0¢ 32.5¢ 31.5¢ $27.30K 84.24K

Buyers (Bids)

No. Vol. Price($)
1 8000 31.5¢
 

Sellers (Offers)

Price($) Vol. No.
32.5¢ 33091 1
View Market Depth
Last trade - 15.32pm 31/05/2024 (20 minute delay) ?
Last
31.5¢ 		  Change
0.000 ( 1.22 %)
Open High Low Volume
32.5¢ 32.5¢ 31.5¢ 23921
Last updated 15.48pm 31/05/2024 ?
BB1 (ASX) Chart

Top Stories

Talga shows expansion options for Sweden's Vittangi graphite project

Talga Group Ltd has completed an expansion study on mining at its Vittangi Graphite Project in Sweden's northeast.
Making the best of an inflationary environment With the latest inflation figures higher than expected this week, the RBA has warned it does not foresee any interest rate cuts until the end of 2024.
Little Green Pharma's cannabis sales leap 30% Little Green Pharma saw sales leap 30% to $25.6 million in the financial year to March 31 witjh flower sales soaring 72% in Australia.
Daily ASX Market Close: Late run sees market lift 1%, May 31, 2024 The ASX200 took a late uptick to be add almost a per cent at close this afternoon. Burritos giant Guzman y Gomez has fast-tracked its move to the ASX – looking to list next month
Thor reports 200% increase in tungsten at NT's Molyhil Thor Energy Plc has reported a 200% increase in contained tungsten in the measured category at its Molyhil project in the Northern Territory.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.